

Oncology Today with Dr Neil Love: PARP Inhibitors in Ovarian Cancer (Video)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Based on results from the Phase III PAOLA-1 trial, which of the following combination regimens is FDA approved as maintenance therapy for a patient with homologous recombination-deficient (HRD) advanced ovarian cancer (OC) after a response to front-line platinum-based chemotherapy with bevacizumab?**
 - a. Rucaparib/bevacizumab
 - b. Olaparib/bevacizumab**
 - c. Veliparib/cediranib
- 2. On the basis of results from the Phase III PRIMA study, the PARP inhibitor niraparib is approved as maintenance therapy after complete or partial response to front-line platinum-based chemotherapy for which of the following subgroups of women with advanced OC?**
 - a. Patients with HRD tumors only
 - b. Patients with homologous recombination-proficient (HRP) tumors only
 - c. Patients with either HRD or HRP tumors**
- 3. How often should complete blood counts be monitored in the first month of initiating niraparib therapy in patients with advanced OC?**
 - a. Monthly
 - b. Every 2 weeks
 - c. Weekly**
- 4. PARP inhibitor therapy is associated with an increased risk of developing which of the following conditions for patients with OC?**
 - a. Myelodysplastic syndromes/ acute myeloid leukemia**
 - b. Interstitial lung disease/ pneumonitis
 - c. Ocular toxicities